Terms: = Brain cancer AND MLH1, COCA2, 4292, ENSG00000076242, hMLH1, FCC2, HNPCC2, P40692, MGC5172, HNPCC AND Treatment
66 results:
1. [Expression of immune checkpoints PD-L1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status].
Naumov SS; Krakhmal NV; Tashireva LA; Vtorushin SV
Arkh Patol; 2024; 86(2):6-13. PubMed ID: 38591901
[TBL] [Abstract] [Full Text] [Related]
2. Exploring the combined anti-cancer effects of sodium butyrate and celastrol in glioblastoma cell lines: a novel therapeutic approach.
Kartal B; Denizler-Ebiri FN; Güven M; Taşpınar F; Canpınar H; Çetin S; Karaduman T; Küççüktürk S; Castresana J; Taşpınar M
Med Oncol; 2024 Mar; 41(5):97. PubMed ID: 38532150
[TBL] [Abstract] [Full Text] [Related]
3. Epigenetic mlh1 silencing concurs with mismatch repair deficiency in sporadic, naturally occurring colorectal cancer in rhesus macaques.
Deycmar S; Johnson BJ; Ray K; Schaaf GW; Ryan DP; Cullin C; Dozier BL; Ferguson B; Bimber BN; Olson JD; Caudell DL; Whitlow CT; Solingapuram Sai KK; Romero EC; Villinger FJ; Burgos AG; Ainsworth HC; Miller LD; Hawkins GA; Chou JW; Gomes B; Hettich M; Ceppi M; Charo J; Cline JM
J Transl Med; 2024 Mar; 22(1):292. PubMed ID: 38504345
[TBL] [Abstract] [Full Text] [Related]
4. Constitutional Mismatch Repair Deficiency Syndrome as a Cause of Numerous Malignancies in a Teenage Patient-A Case Report.
Samborska M; Galli D; Achkar R; Thambyrajah S; Derwich K
J Pediatr Hematol Oncol; 2023 Oct; 45(7):e917-e920. PubMed ID: 37526375
[TBL] [Abstract] [Full Text] [Related]
5. The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
Güven M; Taşpınar F; Denizler-Ebiri FN; Castresana JS; Taşpınar M
Med Oncol; 2023 Jul; 40(8):223. PubMed ID: 37403006
[TBL] [Abstract] [Full Text] [Related]
6. Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma.
Benusiglio PR; Elder F; Touat M; Perrier A; Sanson M; Colas C; Guerrini-Rousseau L; Tran DT; Trabelsi N; Carpentier C; Marie Y; Adam C; Bernier M; Cazals-Hatem D; Mokhtari K; Tran S; Mathon B; Capelle L; Dhooge M; Idbaih A; Alentorn A; Houillier C; Dehais C; Hoang-Xuan K; Cuzzubbo S; Carpentier A; Duval A; Coulet F; Bielle F
JCO Precis Oncol; 2023 May; 7():e2200525. PubMed ID: 37262394
[TBL] [Abstract] [Full Text] [Related]
7. Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors.
Shinojima N; Ozono K; Yamamoto H; Abe S; Sasaki R; Tomita Y; Kai A; Mori R; Yamamoto T; Uekawa K; Matsui H; Nosaka K; Matsuzaki H; Komohara Y; Mikami Y; Mukasa A
Brain Tumor Pathol; 2023 Jul; 40(3):185-190. PubMed ID: 37086325
[TBL] [Abstract] [Full Text] [Related]
8. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
[TBL] [Abstract] [Full Text] [Related]
9. Molecular characterization of gastric adenocarcinoma diagnosed in patients previously treated for Hodgkin lymphoma or testicular cancer.
Rigter LS; Snaebjornsson P; Rosenberg EH; Altena E; van Grieken NCT; Aleman BMP; Kerst JM; Morton L; Schaapveld M; Meijer GA; van Leeuwen FE; van Leerdam ME;
PLoS One; 2022; 17(7):e0270591. PubMed ID: 35877698
[TBL] [Abstract] [Full Text] [Related]
10. Microsatellite Instability-High Endometrial cancers with mlh1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles.
Manning-Geist BL; Liu YL; Devereaux KA; Paula ADC; Zhou QC; Ma W; Selenica P; Ceyhan-Birsoy O; Moukarzel LA; Hoang T; Gordhandas S; Rubinstein MM; Friedman CF; Aghajanian C; Abu-Rustum NR; Stadler ZK; Reis-Filho JS; Iasonos A; Zamarin D; Ellenson LH; Lakhman Y; Mandelker DL; Weigelt B
Clin Cancer Res; 2022 Oct; 28(19):4302-4311. PubMed ID: 35849120
[TBL] [Abstract] [Full Text] [Related]
11. Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillance.
Hamblin R; Vardon A; Akpalu J; Tampourlou M; Spiliotis I; Sbardella E; Lynch J; Shankaran V; Mavilakandy A; Gagliardi I; Meade S; Hobbs C; Cameron A; Levy MJ; Ayuk J; Grossman A; Ambrosio MR; Zatelli MC; Reddy N; Bradley K; Murray RD; Pal A; Karavitaki N
Lancet Diabetes Endocrinol; 2022 Aug; 10(8):581-588. PubMed ID: 35780804
[TBL] [Abstract] [Full Text] [Related]
12. cancer Risk C (CR-C), a functional genomics test is a sensitive and rapid test for germline mismatch repair deficiency.
Alim I; Loke J; Yam S; Templeton AS; Newcomb P; Lindor NM; Pai RK; Jenkins MA; Buchanan DD; Gallinger S; Klugman S; Ostrer H
Genet Med; 2022 Sep; 24(9):1821-1830. PubMed ID: 35616648
[TBL] [Abstract] [Full Text] [Related]
13. DNA Mismatch Repair-deficient Rectal cancer Is Frequently Associated With Lynch Syndrome and With Poor Response to Neoadjuvant Therapy.
Farchoukh LF; Celebrezze J; Medich D; Cunningham K; Holder-Murray J; Holtzman M; Lee K; Choudry H; Pai RK
Am J Surg Pathol; 2022 Sep; 46(9):1260-1268. PubMed ID: 35551135
[TBL] [Abstract] [Full Text] [Related]
14. Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report.
Shah S; Manzoor S; Rothman Y; Hagen M; Pater L; Golnik K; Mahammedi A; Lin AL; Bhabhra R; Forbes JA; Sengupta S
Neurosurgery; 2022 Aug; 91(2):e51-e56. PubMed ID: 35544035
[TBL] [Abstract] [Full Text] [Related]
15. Histopathological and genetic features of mismatch repair-deficient high-grade prostate cancer.
Wyvekens N; Tsai HK; Sholl LM; Tucci J; Giannico GA; Gordetsky JB; Hirsch MS; Barletta JA; Acosta AM
Histopathology; 2022 Jun; 80(7):1050-1060. PubMed ID: 35395112
[TBL] [Abstract] [Full Text] [Related]
16. Expression of Programmed Cell Death-L1 (PD-L1) Protein and Mismatch Repair Mutations in Orbital Tumours-a Pilot Study.
AlSemari MA; Strianese D; Abu Safieh L; Al Hussain H; Abedalthagafi M; Edward DP
Eur J Ophthalmol; 2022 Sep; 32(5):3097-3102. PubMed ID: 34931541
[TBL] [Abstract] [Full Text] [Related]
17. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic cancers.
Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C
Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958
[TBL] [Abstract] [Full Text] [Related]
18. Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors.
Kim H; Lim KY; Park JW; Kang J; Won JK; Lee K; Shim Y; Park CK; Kim SK; Choi SH; Kim TM; Yun H; Park SH
Lab Invest; 2022 Feb; 102(2):160-171. PubMed ID: 34848827
[TBL] [Abstract] [Full Text] [Related]
19. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.
Salewski I; Henne J; Engster L; Schneider B; Lemcke H; Skorska A; Berlin P; Henze L; Junghanss C; Maletzki C
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206051
[TBL] [Abstract] [Full Text] [Related]
20. Mismatch repair-deficient prostate cancer with parenchymal brain metastases treated with immune checkpoint blockade.
Sena LA; Salles DC; Engle EL; Zhu Q; Tukachinsky H; Lotan TL; Antonarakis ES
Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34140335
[TBL] [Abstract] [Full Text] [Related]
[Next]
